Question · asked by 1 review
Anti‐IL‐5 mAb (mepolizumab) vs placebo (on top of topical steroids): Adverse events ‐ nasopharyngitis, including sore throat
- Population
- patients with severe chronic rhinosinusitis with nasal polyps
- Intervention
- Anti‐IL‐5 mAb (mepolizumab)
- Comparison
- placebo (on top of topical steroids)
- Outcome
- Adverse events ‐ nasopharyngitis, including sore throat
Anti‐IL‐5 mAb (mepolizumab) showed no clear difference in adverse events ‐ nasopharyngitis, including sore throat compared with placebo (on top of topical steroids) (low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Anti‐IL‐5 mAb (mepolizumab) vs placebo (on top of topical steroids) Adverse events ‐ nasopharyngitis, including sore throat · patients with severe chronic rhinosinusitis with nasal polyps Anti‐IL‐5 mAb (mepolizumab) showed no clear difference in adverse events ‐ nasopharyngitis, including sore throat compared with placebo (on top of topical steroids) (low certainty). Biologics for chronic rhinosinusitis (2021) · Cochrane Headline outcomes only | RR 0.73 [0.36, 1.47] | 2 studies · 135 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.